S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
"Prepare for Five Years of Famine" (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
"Prepare for Five Years of Famine" (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
"Prepare for Five Years of Famine" (Ad)
Union Pacific 2nd railroad to drop push for one-person crews
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
"Prepare for Five Years of Famine" (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
"Prepare for Five Years of Famine" (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
"Prepare for Five Years of Famine" (Ad)
Union Pacific 2nd railroad to drop push for one-person crews
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
"Prepare for Five Years of Famine" (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
"Prepare for Five Years of Famine" (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
"Prepare for Five Years of Famine" (Ad)
Union Pacific 2nd railroad to drop push for one-person crews
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
"Prepare for Five Years of Famine" (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
"Prepare for Five Years of Famine" (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
"Prepare for Five Years of Famine" (Ad)
Union Pacific 2nd railroad to drop push for one-person crews
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:SESN

Sesen Bio - SESN Stock Forecast, Price & News

$0.63
+0.04 (+7.29%)
(As of 03/7/2023)
Add
Compare
Today's Range
$0.57
▼
$0.63
50-Day Range
$0.63
▼
$12.99
52-Week Range
$0.37
▼
$0.97
Volume
1.87 million shs
Average Volume
1.07 million shs
Market Capitalization
$127.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Sesen Bio MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$842,886 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.09) to ($0.03) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.48 out of 5 stars

Medical Sector

968th out of 995 stocks

Pharmaceutical Preparations Industry

468th out of 482 stocks

See Top Rated MarketRank™ Stocks Here

SESN stock logo

About Sesen Bio (NASDAQ:SESN) Stock

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Receive SESN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter.

SESN Stock News Headlines

March 25, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Sesen Bio (NASDAQ:SESN)
March 6, 2023 | bizjournals.com
After revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Bio
March 27, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
March 2, 2023 | msn.com
Sesen Bio wins shareholder approval for Carisma merger
March 2, 2023 | finance.yahoo.com
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
February 28, 2023 | finance.yahoo.com
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
February 24, 2023 | benzinga.com
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations
February 21, 2023 | finance.yahoo.com
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma
March 27, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
February 16, 2023 | businesswire.com
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
February 16, 2023 | finance.yahoo.com
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
February 15, 2023 | finance.yahoo.com
5 big dividend moves: Group 1 Automotive hikes by 20% | Pro Recap
February 15, 2023 | finance.yahoo.com
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
February 14, 2023 | bizjournals.com
Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group
February 14, 2023 | msn.com
Sesen gains 11% on amended terms for merger with Carisma
February 14, 2023 | finance.yahoo.com
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
February 6, 2023 | finance.yahoo.com
Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years ago
February 2, 2023 | finance.yahoo.com
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
February 2, 2023 | finance.yahoo.com
The Petri Dish: Departed White House adviser returns to the Broad
January 30, 2023 | finance.yahoo.com
Sesen Bio Receives NASDAQ Delisting Notice
January 26, 2023 | finance.yahoo.com
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
January 19, 2023 | finance.yahoo.com
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
January 6, 2023 | benzinga.com
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations
January 5, 2023 | finance.yahoo.com
Investor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger
January 4, 2023 | finance.yahoo.com
Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics
January 3, 2023 | msn.com
Sesen Bio investors reiterate plan to vote against Carisma merger
January 3, 2023 | finance.yahoo.com
Carisma Therapeutics and Sesen Bio merger draws opposition from large shareholder
See More Headlines
Receive SESN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter.

SESN Company Calendar

Last Earnings
11/07/2021
Today
3/26/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SESN
CUSIP
N/A
CIK
1485003
Web
www.sesenbio.com
Phone
(617) 444-8550
Fax
617-858-0911
Employees
35
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,880,000.00
Net Margins
N/A
Pretax Margin
-59.40%
Return on Equity
6.70%
Return on Assets
5.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.10
Quick Ratio
6.10

Sales & Book Value

Annual Sales
$40 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
3.39
Book Value
$0.78 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
203,490,000
Free Float
196,980,000
Market Cap
$127.96 million
Optionable
Optionable
Beta
0.83

Key Executives

  • Thomas R. Cannell
    President, Chief Executive Officer & Director
  • Monica Forbes
    Chief Financial Officer & Treasurer
  • Stephanie Vigue
    Finance Director
  • Jeannick Cizeau
    Head of Research
  • Glen C. MacDonald
    Chief Technology Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SESN Stock - Frequently Asked Questions

When is Sesen Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our SESN earnings forecast.

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) issued its earnings results on Sunday, November, 7th. The company reported $7.20 earnings per share for the quarter, topping the consensus estimate of ($1.40) by $8.60.

When did Sesen Bio's stock split?

Shares of Sesen Bio reverse split on the morning of Wednesday, March 8th 2023. The 1-20 reverse split was announced on Wednesday, March 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK).

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

Who are Sesen Bio's major shareholders?

Sesen Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (4.06%), Millennium Management LLC (0.51%), Renaissance Technologies LLC (0.50%), Group One Trading L.P. (0.00%), Susquehanna International Group LLP (0.00%) and Blodgett Wealth Advisors LLC (0.30%). Insiders that own company stock include Elly Ryu, Glen C Macdonald, Mark Sullivan, Monica Forbes and Thomas R Cannell.
View institutional ownership trends.

How do I buy shares of Sesen Bio?

Shares of SESN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Sesen Bio make?

Sesen Bio (NASDAQ:SESN) has a market capitalization of $0.00 and generates $40 million in revenue each year. The company earns $-19,880,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The official website for the company is www.sesenbio.com. The company can be reached via phone at (617) 444-8550, via email at ir@sesenbio.com, or via fax at 617-858-0911.

This page (NASDAQ:SESN) was last updated on 3/27/2023 by MarketBeat.com Staff